Tourette's syndrome improvement with pergolide in a randomized, double- blind, crossover trial

Neurology

Volumn 54, Issue 6, 2000, Pages 1310-1315

  Gilbert, Donald L ^b   Sethuraman, G ^c   Sine, L ^a   Peters, S ^c   Sallee, F R ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c NONE

Author keywords

Children; D1 receptor; D2 receptor; D3 receptor; Dopamine agonist; Pergolide; Pharmacotherapy; Tourette's syndrome

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE;

ADOLESCENT; ARTICLE; BODY WEIGHT DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HUMAN; IRRITABILITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; SEDATION; SYNCOPE; VERTIGO;

EID: 0034724154     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.6.1310     Document Type: Article

References (33)

1. Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1989;46:722-730.
2. Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry 1997;154: 1057-1062.
3. Silva RR, Muñoz DM, Daniel W, Barickman J, Friedhoff AJ. Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives. J Clin Psychiatry 1996;57:129-135.
4. Bruun RD. Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder. Am J Psychiatry 1988;145:621-624.
5. Singer HS. Tardive dyskinesia: a concern for the pediatrician. Pediatrics 1986;77:553-556.
6. Singer HS. Neurobiology of Tourette syndrome. Neurol Clin 1997;15:357-379.
7. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47.
8. Lehmann J, Briley M, Langer SZ. Characterization of dopamine autoreceptor and [3H]spiperone binding sites in vitro with classical and novel dopamine receptor agonists. Eur J Pharmacol 1983;88:11-26.
9. Lipinski JF, Sallee FR, Jackson C, Sethuraman G. Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide. Mov Disord 1997;12:402-407.
10. Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of 1 tic severity. J Am Acad Child Adolesc Psychiatry 1989;28: 566-573.
11. Cohen DJ, Leckman JF, Shaywitz BA. The Tourette syndrome and other tics. eds. Shaffer D, Ehrhardt AA, Greenhill LL. In: The Clinical Guide to Child Psychiatry. New York: Free Press, 1985, 3-26.
12. Leckman JF, Towbin KE, Ort SI, Swartz KL, Stevenson J, Cohen DJ. Clinical assessment of tic disorder severity. In: Cohen DJ, Bruun RD, Leckman JF, eds. Tourette's Syndrome and Tic Disorders: Clinical Understanding and Treatment. New York: Wiley & Sons, 1989:56-58.
13. US Food and Drug Administration. "COSTART" Coding Symbols Thesaurus of Adverse Reaction Terms. 4th ed. 1993.
14. Guy W. ECDEU Assessment Manual for Psychopharmacology United States Department of Health, Education, and Welfare, Washington D.C. 1976:634-637.
15. Grizzle JE. The two period change-over design and its use in clinical trials. Biometrics 1965;21:467-480.
16. Jones B, Kenward M. Design and Analysis of Cross-over Trials. London:Chapman and Hall, 1989.
17. Brown WB. The crossover experiment for clinical trials. Biometrics 1980;36:69-79.
18. Griesemer DA. Pergolide in the management of Tourette syndrome. J Child Neurol 1997;12:402-403.
19. Berg MJ, Ebert B, Willis DK, Host T, Fincham RW, Schottelius DD. Parkinsonism - drug treatment. Part II. Drug Intell Clin Pharm 1987;21:167-172.
20. Kurlan R, Miller C, Knapp R, Murphy G, Shoulson I. Double-blind assessment of potential pergolide-induced cardiotoxicity. Neurology 1986;36:993-995.
21. Feinberg M, Carroll BJ. Effects of dopamine agonists and antagonists in Tourette's disease. Arch Gen Psychiatry 1979; 36:979-985.
22. Arnt J, Hyttel J. Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats. Psychopharmacology (Berl) 1985;85:346-352.
23. Perachon S, Schwartz JC, Sokoloff P. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. Eur J Pharmacol 1999;366:293-300.
24. White FJ, Wang RY. A10 dopamine neurons: role of autoreceptors in determining firing rate and sensitivity to dopamine agonists. Life Sci 1984;34:1161-1170.
25. Stamford JA, Kruk ZL, Millar J. Differential effects of dopamine agonists upon stimulated limbic and striatal dopamine release: in vivo voltametric data. Br J Pharmacol 1991;102: 45-50.
26. Dethy S, Laute MA, Luxen A, Hildebrand J, Goldman S. Effect of pergolide on endogenous and exogenous L-DOPA metabolism in the rat striatum: a microdialysis study. J Neural Transm Gen Sect 1995;101:1-11.
27. Ziemann U, Paulus W, Rothenberger A. Decreased motor inhibition in Tourette's disorder: evidence from transcranial magnetic stimulation. Am J Psychiatry 1997;154:1277-1284.
28. Ziemann U, Tergau F, Bruns D, Baudewig J, Paulus W. Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs. Electroencephalogr Clin Neurophysiol 1997;105:430-437.
29. Carter AJ, Muller RE. Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol 1991;200:65-72.
30. Goetz CG, Stebbins GT, Thelen JA. Talipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo-controlled clinical trial. Mov Disord 1994;9:315-317.
31. Svensson K, Carlsson A, Huff RM, Kling-Petersen T, Waters N. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur J Pharmacol 1994;263:235-243.
32. Earley CJ, Yaffee JB, Allen RP. Randomized, double-blind, placebo-controlled trial of pergolide in restless legs syndrome. Neurology 1998;51:1599-1602.
33. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999;52:938-943.